PFE vs RMD

Pfizer Inc. remains a mature, large-cap pharmaceutical company with limited potential for the requested 10x growth within 3-5 years, which would require a market cap exceeding $1.4 trillion. While Q1 2026 results showed revenue of $14.45B and adjusted EPS of $0.75, both beating estimates, YoY revenue growth was modest at +5.4% and adjusted EPS declined -18%. Strategic legal wins for VYNDAQEL and C...

ResMed Inc. (RMD) continues to demonstrate robust performance as a global leader in sleep apnea and respiratory care. Its Q3 FY2026 results showed healthy 10.8% YoY revenue growth, EPS beat ($2.86 vs $2.79 consensus), and gross margin expansion to 62.8%. These are strong indicators of a well-managed, profitable company in an established healthcare sector. However, this analysis specifically target...